摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-aminonoscapine | 1214255-25-0

中文名称
——
中文别名
——
英文名称
9-aminonoscapine
英文别名
Amino-noscapine;(3S)-3-[(5R)-9-amino-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6,7-dimethoxy-3H-2-benzofuran-1-one
9-aminonoscapine化学式
CAS
1214255-25-0
化学式
C22H24N2O7
mdl
——
分子量
428.442
InChiKey
FBJIWQULMXAMBV-SJORKVTESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    31
  • 可旋转键数:
    4
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    102
  • 氢给体数:
    1
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    9-aminonoscapine亚硝酸特丁酯叠氮基三甲基硅烷 作用下, 以 乙腈 为溶剂, 反应 36.0h, 以74%的产率得到9-azido-α-noscapine
    参考文献:
    名称:
    微管蛋白阻聚剂9-叠氮基-α-诺斯卡汀的合成及点击反应
    摘要:
    摘要 在温和的反应条件下(亚硝酸 叔 丁酯/叠氮化三甲基甲硅烷基叠氮化物在室温下),开发了一种由9-氨基-α-芥子 碱 2g 合成微管蛋白聚合抑制剂9-叠氮基-α-芥子碱 2h的有效方法 。该协议的优点是操作简单,产品产率高而不形成任何副产品。进一步的铜催化的9-叠氮基-α-芥子碱 2h 与炔烃 6a-f的 点击反应 产生了9-三唑基类胡萝卜素 7a-f, 产生了优异的收率。图形概要 开发了在温和的反应条件下由9-氨基-α-芥子碱合成9-叠氮基-α-芥子碱的友好协议;使用点击化学将其进一步衍生为三唑。
    DOI:
    10.1007/s11164-016-2773-7
  • 作为产物:
    描述:
    那可汀copper(l) iodide 、 sodium azide 、 氢溴酸N,N'-二甲基乙二胺 作用下, 以 乙醇 为溶剂, 反应 8.0h, 生成 9-aminonoscapine
    参考文献:
    名称:
    微管蛋白阻聚剂9-叠氮基-α-诺斯卡汀的合成及点击反应
    摘要:
    摘要 在温和的反应条件下(亚硝酸 叔 丁酯/叠氮化三甲基甲硅烷基叠氮化物在室温下),开发了一种由9-氨基-α-芥子 碱 2g 合成微管蛋白聚合抑制剂9-叠氮基-α-芥子碱 2h的有效方法 。该协议的优点是操作简单,产品产率高而不形成任何副产品。进一步的铜催化的9-叠氮基-α-芥子碱 2h 与炔烃 6a-f的 点击反应 产生了9-三唑基类胡萝卜素 7a-f, 产生了优异的收率。图形概要 开发了在温和的反应条件下由9-氨基-α-芥子碱合成9-叠氮基-α-芥子碱的友好协议;使用点击化学将其进一步衍生为三唑。
    DOI:
    10.1007/s11164-016-2773-7
点击查看最新优质反应信息

文献信息

  • In silico inspired design and synthesis of a novel tubulin-binding anti-cancer drug: folate conjugated noscapine (Targetin)
    作者:Pradeep K. Naik、Manu Lopus、Ritu Aneja、Surya N. Vangapandu、Harish C. Joshi
    DOI:10.1007/s10822-011-9508-z
    日期:2012.2
    for cellular folate receptor alpha (FRα). FRα is over-expressed on some solid tumours such as ovarian epithelial cancers. Molecular docking experiments predicted that a folate conjugated noscapine (Targetin) accommodated well inside the binding cavity (docking score -11.295 kcal/mol) at the interface between α- and β-tubulin. The bulky folate moiety of Targetin is extended toward lumen of microtubules
    我们筛选不会解聚大量细胞微管的微管蛋白结合小分子,但基于众所周知的微管解聚秋水仙碱和鬼臼毒素的结构特征,揭示了那可碱的微管蛋白结合抗癌特性(Ye 等人在 Proc Natl Acad Sci美国 95:2280-2286, 1998)。在分子建模计算和构效关系的指导下,我们在诺斯卡品的 C9 处结合,叶酸基团 - 细胞叶酸受体 α (FRα) 的配体。FRα 在一些实体瘤如卵巢上皮癌中过度表达。分子对接实验预测,结合叶酸的那可品 (Targetin) 在 α- 和 β- 微管蛋白之间的界面处很好地容纳在结合腔内(对接分数 -11.295 kcal/mol)。Targetin 庞大的叶酸部分向微管腔延伸。基于分子力学能量最小化计算的结合自由能 (ΔG (bind)) 为 -221.01 kcal/mol,表明 Targetin 与受体之间存在良好的相互作用。化学合成、微管蛋白结合实验和体外抗
  • 9-PAN promotes tubulin- and ROS-mediated cell death in human triple-negative breast cancer cells
    作者:Prachi Verma、Praveen Kumar Reddy Nagireddy、Shweta Shyam Prassanawar、Jesuthankaraj Grace Nirmala、Ankita Gupta、Srinivas Kantevari、Manu Lopus
    DOI:10.1111/jphp.13349
    日期:2020.10.6
    Abstract Objectives

    To examine the antiproliferative effect of a rationally designed, novel noscapine analogue, 9-((perfluorophenyl)methylene) aminonoscapine, ‘9-PAN’) on MDA-MB-231 breast cancer cell line, and to elucidate the underlying mechanism of action.

    Methods

    The rationally designed Schiff base-containing compound, 9-PAN, was characterized using IR, NMR and mass spectra analysis. The effect of the compound on cell viability was studied using an MTT assay. Cell cycle and cell death analyses were performed using flow cytometry. Binding interactions of 9-PAN with tubulin were studied using spectrofluorometry. Reactive oxygen species (ROS) generation and mitochondrial membrane potential (MMP) were investigated using the probes, DCFDA and rhodamine-123, respectively. Immunofluorescence imaging was used to visualize cellular microtubules.

    Key findings

    9-PAN inhibited cell proliferation (IC50 of 20 ± 0.3 µm) and colony formation (IC50, 6.2 ± 0.3 µm) by arresting the cells at G2/M phase of the cell cycle. It bound to tubulin in a concentration-dependent manner without considerably altering the tertiary conformation of the protein or the polymer mass of the microtubules in vitro. The noscapinoid substantially damaged cellular microtubule network and induced cell death, facilitated by elevated levels of ROS.

    Conclusions

    9-PAN exerts its antiproliferative effect by targeting tubulin and elevating ROS level in the cells.

    摘要 目的 检验一种经过合理设计的新型诺斯卡平类似物9-((全氟苯基)亚甲基)氨基诺斯卡平('9-PAN')对MDA-MB-231乳腺癌细胞系的抗增殖作用,并阐明其作用机制。 方法 通过红外光谱、核磁共振和质谱分析对经过合理设计的含席夫碱基团的化合物9-PAN进行表征。使用MTT实验研究该化合物对细胞存活率的影响。利用流式细胞术进行细胞周期和细胞死亡分析。使用荧光光谱法研究9-PAN与微管蛋白的结合相互作用。分别使用探针DCFDA和罗丹明-123研究9-PAN引起的活性氧(ROS)生成和线粒体膜电位(MMP)。利用免疫荧光成像来可视化细胞微管。 主要发现 9-PAN通过阻滞细胞在细胞周期的G2/M期停滞,抑制了细胞增殖(IC50为20 ± 0.3 µm)和克隆形成(IC50为6.2 ± 0.3 µm)。它以浓度依赖的方式结合到微管蛋白,而在体外并未显著改变蛋白的三级构象或微管的聚合物质量。这种诺斯卡平类似物显著破坏了细胞微管网络并诱导细胞死亡,这是由于ROS水平升高而促进的。 结论 9-PAN通过作用于微管并提高细胞内ROS水平来发挥其抗增殖作用。
  • 9-AMINONOSCAPINE AND ITS USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS
    申请人:Joshi Harish C.
    公开号:US20110294844A1
    公开(公告)日:2011-12-01
    9-aminonoscapine, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-aminonoscapine, and methods of preparation and use thereof are disclosed. 9-aminonoscapine is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. 9-aminonoscapine can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, 9-aminonoscapine is a novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs.
    9-氨基诺斯卡平,其前药物以及其药用盐已被披露。包括9-氨基诺斯卡平的药物组合物,以及其制备和使用方法也已被披露。9-氨基诺斯卡平是一种诺斯卡平类似物,可用于治疗和/或预防各种癌症,包括对紫杉醇、长春新碱和替尼泊苷耐药的癌细胞(卵巢和T细胞淋巴瘤),通过结合微管蛋白并选择性诱导肿瘤细胞凋亡。9-氨基诺斯卡平可以通过有丝分裂阻滞扰乱细胞周期的进展,随后伴随着增加的caspase-3激活和TUNEL阳性细胞的出现而导致细胞凋亡。因此,9-氨基诺斯卡平是一种新型的治疗剂,可用于治疗各种癌症,包括卵巢和T细胞淋巴瘤癌,甚至那些已对当前可用的化疗药物产生耐药性的癌症。
  • Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid
    作者:Pradeep K. Naik、Biswa Prasun Chatterji、Surya N. Vangapandu、Ritu Aneja、Ramesh Chandra、Srinivas Kanteveri、Harish C. Joshi
    DOI:10.1007/s10822-011-9430-4
    日期:2011.5
    bond. Also the patterns of non-bonded interactions are albeit different between both the lignads. The 'blind docking' approach (docking of ligand with different binding sites of a protein and their evaluations) as well as the reasonable accuracy of calculating ΔG (bind) using LIE-SGB model constitutes the first evidence that this class of compounds binds to tubulin at a site overlapping with colchicine-binding
    Noscapine 及其衍生物是重要的微管干扰剂,具有强大的抗肿瘤活性。使用线性相互作用能 (LIE) 方法和表面广义玻恩 (SGB) 连续溶剂化模型计算的 noscapinoids 的结合自由能 (ΔG (bind)) 与实验 ΔG (bind) 一致,平均均方根误差为 0.082千卡/摩尔。这个 LIE-SGB 模型指导我们设计了一种新型的那可丁衍生物,氨基-那可丁 [(S)-3-((R)-9-amino-4-methoxy-6-methyl-5,6,7,8-四氢 [1, 3] 二氧戊环 [4,5-g]isoquinolin-5-yl)-6,7-二甲氧基异苯并呋喃-1(3H)-one] 具有更高的微管蛋白结合活性(预测的 ΔG (bind) = -6.438 kcal/mol 和实验 ΔG (bind) = -6.628 kcal/mol) 比那可品高,但不会显着改变微管蛋白亚基/聚合
  • Rational design of novel <i>N</i> ‐alkyl amine analogues of noscapine, their chemical synthesis and cellular activity as potent anticancer agents
    作者:Rajesh Kumar Meher、Pratyush Pragyandipta、Ravi K. Pedapati、Praveen K. R. Nagireddy、Srinivas Kantevari、Arnab K. Nayek、Pradeep K. Naik
    DOI:10.1111/cbdd.13901
    日期:——
    rationally design and screened three novel 9-(N-arylmethylamino) noscapinoids, 15–17 with robust binding affinity with tubulin. The selected 9-(N-arylmethylamino) noscapinoids revealed improved predicted binding energy of −6.694 kcal/mol for 15, −7.118 kcal/mol for 16 and −7.732 kcal/mol for 17, respectively in comparison to the lead molecule (−5.135 kcal/mol). These novel derivatives were chemically synthesized
    诺斯卡品(镇咳药植物生物碱)的支架结构是由中引起改性Ñ -芳基甲基药效在异喹啉环的C-9位置合理设计和筛选三种新9-(Ñ -arylmethylamino)noscapinoids,15-17具有强大的与微管蛋白的结合亲和力。所选的 9-( N-芳基甲基氨基) 类辣椒素显示出改进的预测结合能,15为-6.694 kcal/mol,16为-7.118 kcal/mol,17为 -7.732 kcal/mol, 分别与铅分子 (-5.135 kcal/mol) 相比。这些新型衍生物是化学合成的,并基于使用两种人类乳腺腺癌 MCF-7 和 MDA-MB-231 以及一组原发性乳腺肿瘤细胞进行的细胞研究验证了它们的抗癌活性。这些衍生物抑制了所有癌细胞的细胞增殖,范围在 3.2 到 32.2 μM 之间,比那可品低 11.9 到 1.8 倍。这些新型衍生物有效地阻止了 G2/M 期的细胞周期,随后是
查看更多

同类化合物

阿托喹啉 那可汀 那可丁N-氧化物 诺司卡品 盐酸盐 水合物 细果角茴香碱 紫堇明 盐酸那可丁一水合物 盐酸诺格考平 盐酸白毛莨碱 曲托喹啉 山缘草定碱 咖喏定 北美黄连碱 [S-(R*,R*)]-6,7-二甲氧基-3-(5,6,7,8-四氢-4-羟基-6-甲基-1,3-二氧杂环戊并[4,5-g]异喹啉-5-基)苯酞 [6S,(+)]-6-[(1S)-1,2,3,4-四氢-6,7-二甲氧基-2-甲基异喹啉-1-基]呋喃并[3,4-e]-1,3-苯并二氧戊环-8(6H)-酮 7-氨基-4,5,6-三乙氧基-3-(6,7,8-三甲氧基-2-甲基-3,4-二氢-1H-异喹啉-1-基)-3H-2-苯并呋喃-1-酮 7-O-去甲基alpha-那可丁 6,7-二甲氧基-3-[(5R)-4-甲氧基-6-甲基-7,8-二氢-5H-[1,3]二氧杂环戊并[4,5-g]异喹啉-5-基]-3H-2-苯并呋喃-1-酮 3-异喹啉-1-基-3H-2-苯并呋喃-1-酮 (3S)-6,7-二甲氧基-3-[(5S)-6-甲基-5,6,7,8-四氢[1,3]二氧杂环戊并[4,5-g]异喹啉-5-基]-2-苯并呋喃-1(3H)-酮 (3S)-3-[(1R)-6,7-二羟基-8-甲氧基-2-甲基-3,4-二氢-1H-异喹啉-1-基]-6,7-二甲氧基-3H-2-苯并呋喃-1-酮 (-)-荷苞牡丹碱甲溴化物 (-)-荷苞牡丹碱 (-)-荷包牡丹碱甲溴化物 (-)-荷包牡丹碱甲氯化物 (-)-紫堇明 (+)-荷苞牡丹碱甲氯化物 (+)-荷包牡丹碱 hydrastidine isohydrastidine 5,9-bis-(4,5-dimethoxy-3-oxo-phthalan-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline (S,R)-9-bromo noscapine (S)-3-{(R)-9-[(2-chloro-acetylamino)-methyl]-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl}-6,7-dimethoxy-phthalide (S)-6,7-dimethoxy-3-{(R)-4-methoxy-6-methyl-9-[(2-morpholino-acetylamino)-methyl]-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl}-phthalide (R)-5-((S)-4,5-dimethoxy-3-oxo-phthalan-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline-9-carboxylic acid methyl ester 4-(((S)-1-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-5-methoxy-3-oxo-1,3-dihydroisobenzofuran-4-yl)oxy)butane-1-sulfonic acid ethyl 4-((5R)-5-((1S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-9-yl)benzoate N-(3-((5R)-5-((1S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-9-yl)phenyl)acetamide (S)-3-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-7-hydroxy-6-methoxyisobenzofuran-1(3H)-one ethyl 2-chloro-5-((5R)-5-((1S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-9-yl)benzoate 3-(((S)-1-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-5-methoxy-3-oxo-1,3-dihydroisobenzofuran-4-yl)oxy)propane-1-sulfonic acid 4-(((S)-5-methoxy-1-((R)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3-oxo-1,3-dihydroisobenzofuran-4-yl)oxy)butane-1-sulfonic acid (3S)-6,7-dimethoxy-3-((5R)-4-methoxy-6-methyl-9-(4-vinylphenyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)isobenzofuran-1(3H)-one (R)-5-((S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline-9-carbaldehyde N-desmethyl-N-carbethoxynarcotine (S)-3-((R)-9-bromo-4-methoxy-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6,7-dimethoxyisobenzofuran-1(3H)-one 9-Fluoro-Noscapine 9-Nitro-Noscapine 7-benzyloxy-6-methoxy-3-(4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one 7-benzyloxy-6-methoxy-3-(4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one